For decades, contraception has been almost exclusively the responsibility of women: hormonal pills, IUDs, implants... Options for men were essentially limited to condoms or vasectomy. But a study published on April 7, 2026 in the Proceedings of the National Academy of Sciences is changing the game. Researchers at Cornell University in the United States have announced a major advance toward a non-hormonal, reversible, and potentially highly effective male contraceptive.

The male pill: a long-elusive scientific "Holy Grail"

Since the 1970s, scientists have sought to develop a male contraceptive that is simultaneously effective, free of serious side effects, and reversible. The hormonal approach — analogous to what exists for women — quickly showed its limitations. Clinical trials based on testosterone or progesterone injections were abandoned due to unacceptable side effects, including mood swings, decreased libido, and lipid disorders.

Researchers therefore turned to non-hormonal pathways: molecules capable of directly interfering with sperm production without affecting the hormones that govern masculinity. This is the direction taken by the team of Professor Paula Cohen, geneticist at Cornell, with results that could mark a decisive turning point in the history of contraception.

JQ1: a molecule that temporarily "switches off" spermatogenesis

The molecule at the heart of the discovery is called JQ1. It is not a brand new substance: JQ1 was already known in oncological research and in the study of inflammatory diseases. But Cornell researchers discovered an unexpected property: it is capable of blocking a specific stage of meiosis, the cell division process by which reproductive cells are formed.

More precisely, JQ1 disrupts the so-called prophase 1 phase, a key step of male meiosis during which chromosomes organize before dividing. By blocking the expression of certain genes necessary for this phase, the molecule completely interrupts spermiogenesis — the final transformation of precursor cells into functional sperm. No hormone is involved in this mechanism, which constitutes the major originality of this approach.

Striking results in mice

In the study, male mice received JQ1 injections for three consecutive weeks. The results were unequivocal: no sperm produced throughout the treatment period, with complete disruption of the molecular parameters of meiosis. In terms of contraceptive efficacy, the rate was 100% in treated animals.

But what impresses scientists most is the total reversibility of the effect. Six weeks after stopping treatment, sperm production had resumed normally. Treated mice were subsequently mated and gave birth to healthy litters. Their offspring were also found to be fertile — proof that there is no transmission of deleterious effects to the next generation.

This combination — total efficacy during treatment and return to normal after cessation — is precisely what researchers had been seeking for decades. "This is the type of result one hopes for, but rarely obtains so clearly", the lead researcher confided.

How would this contraceptive be administered in humans?

Obviously, an injection in mice does not mean a male pill will be available at pharmacies tomorrow. But the Cornell team is already anticipating the forms this contraceptive could take in humans:

• An injection every three months: the most envisioned format to guarantee a sufficient and stable concentration of the molecule in the body, similar to progesterone contraceptive injections used by women.
• A transdermal patch: an alternative to injection, more discreet and practical for daily use, whose design is currently under evaluation.

Professor Cohen and her colleagues plan to create an academic spin-off within the next two years to continue the clinical development of these methods. The next steps will involve trials on non-human primates, then clinical trial phases in humans — a process that typically takes several years, or even an entire decade.

A public health and reproductive equity issue

Beyond the scientific achievement, this research raises a fundamental question: that of sharing the contraceptive burden between men and women. Today, women bear the bulk of contraception, often at the cost of significant side effects: weight gain, migraines, cardiovascular risks, mood disorders, loss of libido...

An effective, hormone-free, reversible male contraceptive would constitute a true revolution in couple dynamics. It would offer men the opportunity to take an active role in family planning, and women a welcome alternative to years of hormonal contraception.

Surveys conducted in several European countries show that more than 60% of men surveyed say they would be willing to use a non-hormonal male contraceptive if it were available, safe, and practical. The social demand clearly exists; it is the scientific supply that has been slow to meet it.

Why this discovery stands out from previous ones

This is not the first time promising advances have been announced in the field of male contraception. Several molecules have raised hopes before being abandoned due to side effects or insufficient efficacy. What sets JQ1 apart, according to its discoverers, is the surgical precision of its mechanism of action: instead of acting on the hormonal system as a whole, it targets a very specific molecular lock in the sperm formation process.

This precise targeting is the key to avoiding the systemic side effects that caused past hormonal approaches to fail. By not interfering with testosterone or the hormones of the hypothalamic-pituitary axis, JQ1 preserves libido, secondary sexual characteristics, and the overall functioning of the body.

A landmark publication

The study was published in the Proceedings of the National Academy of Sciences (PNAS), one of the most prestigious scientific journals in the world. Its release immediately generated a strong international media response, hailed by many experts in reproduction and pharmacology as "a decisive step" toward the male contraception of tomorrow.

There is still a long road ahead before men can benefit from such a method. But for the first time in a long while, the scenario of truly shared contraception seems to be approaching rapidly. A quiet revolution may be underway, at the scale of a chromosome, in the laboratories of Cornell.